Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

74 results about "Pre eclampsie" patented technology

Nitric oxide enhancing diuretic compounds, compositions and methods of use

InactiveUS20060189603A1Antibacterial agentsSenses disorderRenovascular diseaseOsteoporosis treatment
The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and / or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and / or nitrogen via a bond or moiety that cannot be hydrolyzed.
Owner:NICOX SA

Synthetic apelin mimetics for the treatment of heart failure

The invention provides a synthetic polypeptide of Formula I′:or an amide, an ester or a salt thereof, wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Owner:NOVARTIS AG

System and method for detecting preeclampsia

A system and method for detecting preeclampsia in a patient is provided. Also provided is a system and method for diagnosing preeclampsia in a patient prior to the detection of conventional symptoms and / or clinical signs associated with preeclampsia. The preeclampsia detection system of the invention comprises at least one sensor and a processor comprising a preeclampsia recognizer. In certain embodiments, the system farther comprises a user interface.
Owner:CONVERGENT ENG +1

Synthetic linear apelin mimetics for the treatment of heart failure

The invention provides a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13  Ior an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Owner:NOVARTIS AG

Methods of diagnosis using pulse volume measurement

The utility of pulse volume measurement is expanded to detection of many conditions which have previously not been detected or have been detected using more complicated techniques. Such conditions include blood loss, septic shock, cardiogenic shock, neonatal sepsis, patent ductus arteriosus, limb ischemia, intra-aortic balloon pump performance, peripheral vascular disease, congestive heart failure, the effectiveness of vasoactive medications, syncope, dehydration, pre-eclampsia, deep vein thrombosis, thermal injuries, vascular instability due to renal dialysis, compromising of circulation to the hand caused by radial artery harvesting, changes in cardiac output, and hypertension. According to the present invention, such diagnoses can be performed by taking one measurement, by taking measurements over time to detect a change or by taking measurements before and after application of a treatment or stimulus.
Owner:SMITHMARKS INC

Methods for determining the risk of prenatal complications

The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.
Owner:WALLAC

Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy

Cardiovascular disease, including preeclampsia in pregnant women and hypertension in both women and men, are prevented or treated by administering thereto prostacyclin or a prostacyclin analog in combination with one or both of an estrogen and a progestin, which combination is also useful for HRT in peri- and post-menopausal women.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Treatment of pre-eclampsia in pregnant women using targeted apheresis

This invention uses “targeted apheresis” to treat pregnant women who are at risk of developing eclampsia. “Targeted Apheresis” is a process whereby the sFlt-1 receptors responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing either immobilized PIGF, and / or through a cartridge containing immobilized anti-sFlt-1 antibody. The sFlt-1 receptor is bound out and the cleaned blood is returned to the patient Removal of circulating sFlt-1 receptors will diminish the risk of developing eclampsia during pregnancy.
Owner:SMITH HENRY J +1

Gene expression related to preeclampsia

Gene expression patterns contemporaneous with early placental development in the first trimester of preeclamptic versus unaffected pregnancies have been obtained. Observation of differences in these gene expression patterns has allowed the identification of biomarkers that are useful in predicting and monitoring preeclampsia. These biomarkers are also useful in screening potential therapeutics for efficacy in the prevention or treatment of preeclampsia.
Owner:UNIVERSITY OF PITTSBURGH +1

Multifactorial telehealth care pregnancy and birth monitoring

A system for monitoring a fetus in a pregnant woman, and / or the maternal health risk for pregnancies complicated by such as pre-eclampsia and hypertensive disorders is configured to be worn by the pregnant woman, preferably so as to allow monitoring during daily life, e.g. in the form of an adhesive patch. The unit has a sound sensor, e.g. a microphone or accelerometer, to be positioned on the skin of the abdominal area so as to detect a vascular sound from umbilical arteries of the fetus or from the uterine arteries of the pregnant woman. The sound sensor is functionally connected to a processing unit which executes a processing algorithm on the captured vascular sound and extracts a signal parameter accordingly. The processing unit then communicates the signal parameter, e.g. using an audio signal, a visual display or by means of a wired or a wireless data signal.
Owner:VIEWCARE TECH 1 APS

Methods for the detection of preeclampsia

Biomarkers associated with preeclampsia were identified. Nine proteins were identified as being differentially regulated between the control and the under 28-weeks preeclamptic samples. Similarly three proteins were identified as being differentially regulated between the control and the over 28-weeks preeclamptic samples. These 12 proteins can be used as potential biomarkers in the diagnosing andprognosing of preeclampsia.
Owner:UNIV OF WESTERN ONTARIO

Novel serine protease

The invention relates to a enzyme predicted to be a serine protease, which is specifically expressed in association with embryo implantation and placentation in pregnant uterus. The enzyme of the invention is useful in the evaluation of fertility and monitoring of early pregnancy, placental development and function, fetal development, parturition, and conditions such as pre-eclampsia, intrauterine growth restriction, early abortion, abnormal uterine bleeding, endometriosis, and cancers, and may provide a potential target for contraception. It may also be important in diseases of the heart, testis or ovary, and may play a role in muscle function, including cardiac muscle, skeletal muscle, lung and the diaphragm. In addition the enzyme of the invention is useful in the screening of candidate drugs for fertility control or for treatment of fertility-related disorders.
Owner:PRINCE HENRYS INST OF MEDICAL RES

Prediction model for early accurate detection of preeclampsia

The invention discloses a prediction model for early accurate detection of preeclampsia. Through research, it is found that the distribution situation of free DNA in peripheral blood in the region ofa gene transcription start site can reflect the physiological state of pregnant women and fetuses, on the basis that the abundance of free DNA in serum in the region of the gene transcription start site is significantly different between preeclampsia patients and healthy pregnant women, the homogeneity correction is carried out on the abundance of the free DNA, and then by using a machine learningalgorithm and through the optimal combination of different genes, the onset of the preeclampsia can be effectively predicted. Therefore, the screening prediction model of the preeclampsia based on prediction of the free DNA in the peripheral blood and the optimal drone gene combination are constructed, the onset of the preeclampsia can be predicted before preeclampsia clinical symptoms appear, and the model is a relatively noninvasive, economic and convenient method to predict the preeclampsia in the early stage, and has good application prospects in the development of preeclampsia predictionand screening products.
Owner:GUANGZHOU DARUI BIOTECH

Circulating RNA signatures specific to preeclampsia

The present invention includes methods and materials for use in the detection preeclampsia and / or determining an increased risk for preeclampsia in a pregnant female, the method including identifyingin a biosample obtained from the pregnant women a plurality of circulating RNA (C-RNA) molecules.
Owner:ILLUMINA INC

Preeclampsia biomarkers and related systems and methods

Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.
Owner:BIORA THERAPEUTICS INC

Method for jointly detecting sFlt-1/PLGF and HLA-G for detecting pre-eclampsia

The invention relates to a method for jointly detecting sFlt-1 / PLGF and HLA-G for predicting pre-eclampsia. The method comprises the following steps: collecting serum specimen: respectively collecting5-10 ml of venous blood from pregnant women in a pre-eclampsia group and normal pregnant women with same gestational weeks, centrifuging all specimens in a low temperature centrifuge at 3000 rpm for10 min within 4 h, taking the serum and subpackaging in EP tubes, and storing in a refrigerator at minus 80 DEG C for testing; coating: using a 0.05 M PH9.0 carbonate coated buffer solution to diluteantibodies to the protein content of 1-10[mu]g / ml, adding 0.1ml of the diluted antibodies into reaction holes of each polystyrene board, staying overnight at 4 DEG C, discarding the solution in the holes the next day, and washing for 3 times; setting up standard holes and sample holes, washing, and setting up blank holes, negative control holes and positive control holes at the same time; adding enzyme-labeled antibodies; adding 100 [mu]L of horseradish peroxidase-labeled detection antibodies into each of the standard holes and the sample holes except for the blank holes, sealing the reactionholes with microplate sealers, and incubating in a water bath kettle or an incubator at 37 DEG C for 60 min; performing board-washing; adding 50 [mu]L of a substrate A and a substrate B into each of the holes, and measuring OD values of each hole. The method is high in detection specificity and sensitivity.
Owner:卢英

Biomarkers for preeclampsia

The present invention relates to novel biomarkers such as histidine and ketone bodies and methods of use thereof for detecting preeclampsia in pregnant individuals and for identifying individuals at risk at an early stage of pregnancy.
Owner:UNIV OF LEEDS

Methods and systems for treating or preventing pregnancy-related hypertensive disorders

Disclosed are methods and apparatuses for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using ex vivo treatment with an anti-sFlt-1 receptor (sFlt-1) antibody bound to a solid support in order to reduce blood levels of sFlt-1. Further disclosed are the sequences of the heavy chain and light chain CDRs of the anti-sFlt-1 antibodies.
Owner:AGGAMIN LLC

Targeted apheresis using binding agents or ligands immobilized on membranes

This invention teaches a method of targeted apheresis that can be used to treat a variety of different diseases including infectious diseases, autoimmune disorders, and reducing circulating biomarkers associated with certain disorders e.g. pre-eclampsia. This invention discloses the use of apheresis membranes as the support matrix upon which one or more different binding agents (e.g. antibodies, aptamers, binding peptides, soluble receptors), and / or ligands (e.g. antigens, serum proteins, hormones, cytokines and cell markers) are attached. During targeted apheresis the patient's blood will come into contact with one or more of these immobilized binding agents or ligands and any targeted harmful factor in the blood will be bound out of circulation. The cleaned blood is then returned to the patient. Reducing the concentration of the harmful substance in blood will alleviate the symptoms of the disease.
Owner:SMITH HENRY JOHN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products